**Conclusion:** TAD measurement in A4C view by 2D-TTE was highly feasible, reproducible and accurately reflected TA size, even if it was systematically underestimating its maximal diameter. Based on measurements in healthy volunteers, we suggest to consider tricuspid annuloplasty during left-heart valve surgery when TA is more than 2.3cm/m² or 4.2cm in A4C.

0436

**Prevalence and clinical impact of QRS duration in patients with low-flow/low-gradient aortic stenosis due to left ventricular systolic dysfunction**

Frederic Sebag, Nicolas Lellouche, Jean Luc Dubois Randé, Pascal Gueret, Jean Luc Monin

CHU Henri Mondor-APHP, Fédération de cardiologie, Créteil, France

**Aims:** To evaluate the prognostic impact of QRS width in patients with low-flow/low-gradient aortic stenosis (LFL/GAS).

**Methods and Results:** Among 88 consecutive patients referred to our institution for LF/LGAS from September 1994 to March 2007, baseline demographic, clinical, echocardiographic and electrocardiographic data were collected. This population was divided in two groups according to baseline QRS duration (cutoff: QRS2 > 130ms). Follow-up data, including echocardiographic evolution and overall mortality were analyzed. The mean follow-up duration was 3.1 (2.2-6.2) years. In the whole group, 67 patients underwent surgical aortic valve replacement. Forty-nine patients (56%) had a QRS duration ≥130ms. Among operated patients, there was no significant change in QRS duration between baseline and latest follow-up (126±26 vs. 131±25ms; p=0.32). In patients with wider QRS was a strong independent predictor of overall mortality (HR=2.20; CI, 1.15–4.24; p=0.027).

**Conclusion:** Significant intra-ventricular conduction disturbances are common in patients with LF/LGAS and do not recover after aortic valve replacement. QRS duration is strongly associated with mortality in this selected population.

0520

**Percutaneous mitral commissurotomy in patients over 50 years old: immediate and long-term results**

Tounsi Ahmed, Abid Leila, Charfeddine Salma, Abid Dorra, Triki Feteh, Akrout Malek, Mallek Souad, Hammami Rania, Hentati Mourad, Kammoun Samir

CHU Hédi Chaker, Cardiologie, Sfax, Tunisie

**Objective:** Describe the immediate and final outcome of percutaneous mitral balloon commissurotomy (PMC) with Inoue balloon in patients over 50 years old and associate complications with age and Wilkins score.

**Material and methods:** A retrospective and analytic study was performed with a data base of 480 patients. We included all the patients proceeding in our department from January 1998 to December 2012. 75 were > or = 50-years old (group1). Immediate and late outcomes in this group (group 1) were compared with those in the patients aged < 50-years (group 2).

**Results:** Baseline hemodynamic parameters were comparable in the two groups. The Wilkins score was 8 in 11 patients We found a Mitral Valvular Area (MVA) before the PMC proceeding of 0.99cm²±0.2 and 1.87cm²±0.38 post PMC (P < 0.001), with pre procedure transmitral gradient of 12.7±6.05mm Hg and of 4.4±2.3mm Hg post (P < 0.001). Similar significant improvements were seen in group 2. In 72 patients (96%) the immediate proceeding was considered successful. The hemodynamic result was good in 85.3% of group 1 patients. Tamponade occurred in one patient. Mitral regurgitation grade I or II developed in 8 patients and remained stable in 19 patients. These complication rates were comparable to those seen in group 2. A clinical and echocardiographic follow-up was performed in 68 patients (93%). In the group 1, a good result was maintained in 60% of patients after 75.8±40 months of follow-up. Although restenosis was observed in 28% of patients, functional amelioration was obtained in most of cases. Survival free of mitral valve intervention or heart failure ≥ NYHA III was significantly better for patients with good immediate result.

**Conclusions:** PMC is safe and efficacious in elderly patients with symptomatic mitral stenosis. Long-term results are good and related mainly to the quality of the procedure.

0546

**Aortic paravalvular regurgitation after transcatheter valve implantation is associated with worse prognosis**

Radostina Ilievva, Dr Ouzan, Ronen Beeri, Haim Danenberg, Chaim Lotan, Dany Gilon

Hadasah Hebrew University medical Center, Heart Institute, Jerusalem, Israel

**Background:** Aortic stenosis (AS) is increasing in incidence with the aging of the population. Transcatheter Aortic Valve Implantation (TAVI) provides a therapeutic option for patients with severe AS who are high risk surgical candidates. A large proportion of patients undergoing TAVI have at least mild aortic paravalvular regurgitation (APR) following the procedure.

**Objective:** The purpose of this study was to determine the clinical and prognostic significance of paravalvular regurgitation early after TAVI.

**Methods:** Hundred and five patients who underwent TAVI at our center from 9.2008 to 5.2012 were studied retrospectively. Echocardiography before and following the procedure but prior to discharge were reviewed. Aortic and mitral regurgitations were assessed using semi quantitative methods.

**Results:** Among 105 patients who underwent TAVI, twenty four (23%) had significant (moderate and more) APR and eighty one (77%) had non significant (less than moderate) APR. There was no significant difference in the baseline characteristics of the two groups (age, sex, left ventricular ejection fraction, aortic valve area, aortic ventricular gradient, ischemic heart disease, pre-procedural aortic regurgitation). Mean follow up was up to 19 months. The mortality rate was higher in the group with significant PAR as compared with the group without APR (29% versus 11% p≤0.009). The frequency of develop block was more frequent in this group (47% versus 30%, p=0.205).

**Conclusions:** Significant paravalvular aortic regurgitation after TAVI causes worsening of mitral regurgitation and pulmonary hypertension and seems associated with higher risk of pacemaker implantation and mortality. Paravalvular aortic regurgitation has clinical significance beyond the often minimal hemodynamic effects after TAVI.

0549

**Complications of repeat percutaneous mitral valveoplasty**

Saoussen Antit (1), Sanu Fennira (2), Sana Fennira (2), Khedija Mzoughi (2), Ihsen Zaari (2), Fethia Ben Moussa (2), Sondos Kralien (2)

(1) Hôpital FSI La Marsa, Cardiologie, La Marsa, Tunisie – (2) Hôpital Habib Thameur, Cardiologie, Tunis, Tunisie

**Background:** Percutaneous mitral valveoplasty (PMV) has emerged as the procedure of choice in treatment of mitral stenosis and has proved effectiveness in cases of mitral restenosis after surgical commissurotommy. Compared with surgery, PMV is associated with shorter hospital stays, reduced patient discomfort, and significantly lower costs. However, it is unknown whether patients who developed symptomatic mitral restenosis after PMV may benefit from repeat PMV (re-PMV) with safety.

**Objectives:** This study was designed to evaluate the occurrence rate and the predictive factors for severe complications following re-PMV.

**Methods:** Retrospective study from a series of 40 procedures of re-PMV with the Inoue balloon at 8±4 years after prior procedure, performed between
1996 and 2011. A clinical and ultrasound follow-up was achieved in 31 patients with a mean follow-up period of 43±26 months.

Results: The mean age of patients was 43±11 years [23, 63], 87.5% of the population being female (5 men and 35 women). The immediate procedural success was achieved in 31 patients (77.5%). A severe mitral regurgitation (MR) was observed in 3 patients (7.5%). A cerebrovascular stroke occurred in 1 patient (2.5%). No procedure-related death or cardiac tamponade were noted. Only a left atrial area ≤25cm² was linked to high risk of severe MR.

At long-term, mitral restenosis was observed in 13 patients (42%) at 53±30 months [9; 128] after re-PMV, 2 patients presented thromboembolic events (6%) and no death. Only the male had been identified as a predictor of restenosis.

Conclusion: The feasibility of re – PMV with a relatively high procedural success rate and an acceptable complication profile makes it an appealing therapeutic strategy for patients with recurrent valve stenosis. The improved experience of our medical teams, and the systematic use of transoesophageal echocardiography to detect thrombi explain the low incidence of the complications of re-PMV in our study.

0562

Long term outcome of patients with benfluorex-induced mitral regurgitation and first episode of heart failure

Pierre-Philippe Nicol (1), Florent Le Ven (1), Yves Etienne (1), Isabelle Quintin-Roué (2), Eric Bezon (3), Ulric Vinsonneau (4), Martine Gilard (1), Jacques Mansourati (1), Yannick Jobic (1)

(1) CHRU Brest, Cardiologie, Brest, France – (2) CHRU Brest, Cytologie, Anatomopathologie, Brest, France – (3) CHRU Brest, Chirurgie cardiothoracique et vasculaire, Brest, France – (4) Hôpital d’Instruction des Armées, Cardiologie, Brest, France

Aims: Benfluorex’s imputability in drug-induced valvular heart disease (DIVHD) is now well established. However no data about long term clinical and echocardiographic follow-up of patients suffering from benfluorex-related DIVHD are available. The present study was conducted to address this issue.

Methods and results: Between January 2003 and June 2012, after an exhaustive analysis of our database, 20 patients (55±9 years, 90% women, body mass index: 32.9±9 kg/m²) hospitalized for heart failure were retrospectively identified with benfluorex induced moderate or severe mitral regurgitation (MR). Initially 70% of them presented NYHA class III or IV. MR was quantified as moderate in 11, moderate to severe in 9 and severe in one patient. Aortic regurgitation (AR) was also present in 17 patients (85%): mild in 5, moderate in 9 and moderate to severe in 3 patients. During a median follow-up of 7 years, heart failure episodes led to 53388 Valve replacements. Two patients died, one in the surgical group and one in the medical group. Among survivors, NYHA class improved in 6 patients in the surgical group but only in 4 in the medical group. After withdrawal of benfluorex, MR decreased in 7 patients and AR decreased in 5 patients. MR was stable in 3 patients and AR in 4 patients. A worsening of MR was not observed and AR worsened in 2 patients.

Conclusion: After an hospitalization for a first episode of heart failure related to benfluorex-induced MR, patients are exposed to a large number of cardiac events including repeated hospitalizations and death.